RMD Stock Recent News
RMD LATEST HEADLINES
ResMed (RMD) came out with quarterly earnings of $1.64 per share, beating the Zacks Consensus Estimate of $1.63 per share. This compares to earnings of $1.51 per share a year ago.
ResMed's (RMD) respiratory care business continues to drive growth and the adoption of bilevel and other non-invasive ventilator solutions worldwide.
SAN DIEGO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2024 on Thursday, October 26, 2023, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
Investors continue to be optimistic about ResMed (RMD) due to the core business' performance and sustained growth in the SaaS business.
This compares with the Sharpe of 1.3 for the Trefis Reinforced Value portfolio.
ResMed (RMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Outside of a handful of highflying technology stocks, U.S. stocks have been practically flat in 2023, but on Wall Street, some analysts remain as bullish as ever.
ResMed is the global leader in the sleep apnea market. Sales growth accelerated during COVID and again recently as a result of a product recall from its major competitor. Despite a strong last quarter the market has marked the stock down due to concerns about the long term loss of market to GLP-1 medications.
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced its participation in two upcoming conferences.
Some investors in ResMed, which makes machines for people with sleep apnea, think that effective new weight-loss drugs could shrink its addressable market. On ResMed's latest earnings call, CEO Mick Farrell laid out three reasons why he doesn't think the company will feel any impact from those drugs.